A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body shapes and sizes.

Dr Pandey shares key insights on dosing, monitoring, and patient education to sustain therapy and improve outcomes. Essential for cardiologists and PCPs!

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Medicine Weight ...

The overgrown foliage had been hiding an ancient structure. Archaeologists identified the ruins as a pyramid-like building dating back at least 3,800 years, officials said. It has three ...

Background: Despite their potential, Glucagon-like peptide-1 receptor agonists (GLP-1 RA) have not been well studied in cardiac amyloidosis (CA) as randomized trials on GLP-1 RA have excluded patients ...

Semaglutide mimics the action of the natural protein glucagon-like peptide 1(GLP-1), a hormone ... meaning its molecules mimic the structure of GLP-1, binding to its receptor like a counterfeit key ...

Researchers from the Institute of Science Tokyo and Osaka Medical and Pharmaceutical University said that they have developed a peptide that can bind to the spike proteins of SARS-CoV-2 to prevent ...

Lipidated analogues of glucagon-like peptide 1 (GLP-1) have gained enormous attention as long ... This work provides a systematic study of the solubility, structure, oligomerization, and long-term ...